| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Cancer Research and Treatment Search > Browse Articles > Search



Lung and Thoracic cancer
Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer: Insights from Real-World Data
Jeong Yun Jang, Si Yeol Song, Young Seob Shin, Ha Un Kim, Eun Kyung Choi, Sang-We Kim, Jae Cheol Lee, Dae Ho Lee, Chang-Min Choi, Shinkyo Yoon, Su Ssan Kim
Cancer Res Treat. 2024;56(3):785-794.   Published online January 16, 2024    DOI: https://doi.org/10.4143/crt.2023.1014
                        Supplementary         Crossref 1
Head and Neck cancer
Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Hana Kim, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Keunchil Park, Yong Chan Ahn, Dongryul Oh, Myung-Ju Ahn
Cancer Res Treat. 2023;55(4):1104-1112.   Published online May 17, 2023    DOI: https://doi.org/10.4143/crt.2023.502
                        Supplementary         Web of Science 8  Crossref 10
Gynecologic cancer
Genomic and Transcriptomic Characterization Revealed the High Sensitivity of Targeted Therapy and Immunotherapy in a Subset of Endometrial Stromal Sarcoma
Nan Kang, Yinli Zhang, Shichao Guo, Ran Chen, Fangzhou Kong, Shuchun Wang, Mingming Yuan, Rongrong Chen, Danhua Shen, Jianliu Wang
Cancer Res Treat. 2023;55(3):978-991.   Published online February 2, 2023    DOI: https://doi.org/10.4143/crt.2022.1647
                           Web of Science 1  Crossref 2
Genitourinary cancer
Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
Hongsik Kim, Byong Chang Jeong, Joohyun Hong, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Wan Song, Hyun Hwan Sung, Jung Yong Hong, Se Hoon Park
Cancer Res Treat. 2023;55(2):636-642.   Published online October 6, 2022    DOI: https://doi.org/10.4143/crt.2022.343
                           Web of Science 4  Crossref 6
Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy
Ryul Kim, Jung Yong Hong, Jeeyun Lee, Ghee Young Kwon, Byong Chang Jeong, Se Hoon Park
Cancer Res Treat. 2022;54(3):894-906.   Published online November 17, 2021    DOI: https://doi.org/10.4143/crt.2021.854
                        Supplementary         Web of Science 5  Crossref 6
Sarcoma
Clinicopathologic Characteristics and Clinical Outcome of Localized Liposarcoma: A Single-Center Experience over 25 Years and Evaluation of PD-L1 Expression
Heejung Chae, Jeong Eun Kim, Wanlim Kim, Jong-Seok Lee, Si Yeol Song, Min Hee Lee, Hye Won Chung, Kyung-Ja Cho, Joon Seon Song, Jin-Hee Ahn
Cancer Res Treat. 2022;54(2):579-589.   Published online July 6, 2021    DOI: https://doi.org/10.4143/crt.2021.496
                        Supplementary         Web of Science 1  Crossref 1
General
Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell-Mediated Tumor Therapy
Yilei Chen, Hongxing Huang, Yin Liu, Zhanghao Wang, Lili Wang, Quanxiao Wang, Yan Zhang, Hua Wang
Cancer Res Treat. 2022;54(2):362-374.   Published online August 3, 2021    DOI: https://doi.org/10.4143/crt.2021.424
                        Supplementary         Web of Science 4  Crossref 6
Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing
Hai-Yun Wang, Ling Deng, Ying-Qing Li, Xiao Zhang, Ya-Kang Long, Xu Zhang, Yan-Fen Feng, Yuan He, Tao Tang, Xin-Hua Yang, Fang Wang
Cancer Res Treat. 2021;53(4):973-982.   Published online February 18, 2021    DOI: https://doi.org/10.4143/crt.2020.798
                        Supplementary         Web of Science 7  Crossref 7
Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy
Jeongshim Lee, Jee Suk Chang, Mi Ryung Roh, Minkyu Jung, Choong-Kun Lee, Byung Ho Oh, Kee Yang Chung, Woong Sub Koom, Sang Joon Shin
Cancer Res Treat. 2020;52(3):730-738.   Published online February 13, 2020    DOI: https://doi.org/10.4143/crt.2019.598
                        Supplementary         Web of Science 6  Crossref 6
Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
Junho Kang, Jae Ho Jeong, Hee-Sang Hwang, Sang Soo Lee, Do Hyun Park, Dong Wook Oh, Tae Jun Song, Ki-Hun Kim, Shin Hwang, Dae Wook Hwang, Song Cheol Kim, Jin-hong Park, Seung-Mo Hong, Kyu-pyo Kim, Baek-Yeol Ryoo, Changhoon Yoo
Cancer Res Treat. 2020;52(2):594-603.   Published online December 18, 2019    DOI: https://doi.org/10.4143/crt.2019.493
                           Web of Science 50  Crossref 48
Combination Treatment of Stereotactic Body Radiation Therapy and Immature Dendritic Cell Vaccination for Augmentation of Local and Systemic Effects
Chul Won Choi, Min Ho Jeong, You-Soo Park, Cheol-Hun Son, Hong-Rae Lee, Eun-Kyoung Koh
Cancer Res Treat. 2019;51(2):464-473.   Published online June 6, 2018    DOI: https://doi.org/10.4143/crt.2018.186
                        Supplementary         Web of Science 16  Crossref 14
Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
Haa-Na Song, Min Gyu Kang, Jeong Rang Park, Jin-Yong Hwang, Jung Hun Kang, Won Seop Lee, Gyeong-Won Lee
Cancer Res Treat. 2018;50(4):1458-1461.   Published online January 22, 2018    DOI: https://doi.org/10.4143/crt.2017.529
                           Web of Science 13  Crossref 12
Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort
Minkyu Jung, Jeeyun Lee, Tae Min Kim, Dae Ho Lee, Jin Hyung Kang, Sung Young Oh, Soo Jung Lee, Sang Joon Shin
Cancer Res Treat. 2017;49(1):44-53.   Published online April 27, 2016    DOI: https://doi.org/10.4143/crt.2016.024
                           Web of Science 27  Crossref 25
Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy
Sung Han Kim, Weon Seo Park, Sun Ho Kim, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Cancer Res Treat. 2016;48(3):1092-1101.   Published online January 28, 2016    DOI: https://doi.org/10.4143/crt.2015.316
                           Web of Science 22  Crossref 23
Improved Efficacy of a Dendritic Cell-Based Vaccine against a Murine Model of Colon Cancer: The Helper Protein Effect
Amir-Hassan Zarnani, Monireh Torabi-Rahvar, Mahmood Bozorgmehr, Mehri Zareie, Nazanin Mojtabavi
Cancer Res Treat. 2015;47(3):518-526.   Published online November 27, 2014    DOI: https://doi.org/10.4143/crt.2013.241
                           Web of Science 12  Crossref 10
Alpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic Allogeneic Breast Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes against Breast Cancer
Min-Ho Park, Deok-Hwan Yang, Mi-Hyun Kim, Jae-Hong Jang, Yoon-Young Jang, Youn-Kyung Lee, Chun-Ji Jin, Than Nhan Nguyen Pham, Truc Anh Nguyen Thi, Mi-Seon Lim, Hyun-Ju Lee, Cheol Yi Hong, Jung-Han Yoon, Je-Jung Lee
Cancer Res Treat. 2011;43(1):56-66.   Published online March 31, 2011    DOI: https://doi.org/10.4143/crt.2011.43.1.56
                           Crossref 11
The Effect of Immunotherapy Based on Interferon - alpha in Advanced Renal Cell Carcinoma
Seung Hyun Jeon, Sung Goo Chang
J Korean Cancer Assoc. 1999;31(5):986-994.
      
Immunoregulatory Effect of Mesima (R) as an Immunotherapeutic Agent in Stage III Gastric Cancer Patients after Radical Gastrectomy
Jin Pok Kim, Keon Young Lee, Hang Jong Yu, Han Kwang Yang
J Korean Cancer Assoc. 1997;29(3):383-390.
      
Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study
Xiangye Ou, Junyi Wu, Jiayi Wu, Yangkai Fu, Zhenxin Zeng, Shuqun Li, Yinan Li, Deyi Liu, Han Li, Bin Li, Jianyin Zhou, Shaowu Zhuang, Shuqun Cheng, Zhibo Zhang, Kai Wang, Shuang Qu, Maolin Yan
Received October 27, 2023   Accepted April 29, 2024   Published online April 30, 2024
DOI: https://doi.org/10.4143/crt.2023.1165    
[Accepted]
      
Korean Cancer Association
E-Submission
EndNote Output Style
Email Alert
Journal Impact Factor 4.1
SCImago Journal & Country Rank
PubMed Central
MEDLINE/PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
Metadata
ORCID
COPE
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI